The role of cytidine deaminases on innate immune responses against human viral infections

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Vieira, Valdimara C ^a   Soares, Marcelo A ^a,b  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN MESSENGER RNA EDITING CATALYTIC POLYPEPTIDE 3; CYTIDINE DEAMINASE; GAMMA INTERFERON; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; SINGLE STRANDED DNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

BURKITT LYMPHOMA; DNA SEQUENCE; DNA SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME LOCALIZATION; EPSTEIN BARR VIRUS; GENE DOSAGE; GENETIC POLYMORPHISM; HAIRY LEUKOPLAKIA; HAPLOTYPE; HEAT SHOCK RESPONSE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN T CELL LEUKEMIA VIRUS; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE; MALIGNANT TRANSFORMATION; MOLECULAR WEIGHT; MONOCYTE; NONHUMAN; PLASMABLASTIC LYMPHOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROPOSON; RETROVIRUS; REVERSE TRANSCRIPTION; REVIEW; RNA SEQUENCE; RNA TRANSLATION; SHORT INTERSPERSED REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC HYPERMUTATION; STOP CODON; T LYMPHOCYTE; VIRION; VIRUS GENOME; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; WART VIRUS; CHEMISTRY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM;

CYTIDINE DEAMINASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; POLYMORPHISM, GENETIC; VIRUS DISEASES;

EID: 84880159446     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/683095     Document Type: Review

References (239)

1. Iwasaki A., A virological view of innate immune recognition. Annual Review of Microbiology 2012 66 177 196 10.1146/annurev-micro-092611-150203
2. Takeuchi O., Akira S., Innate immunity to virus infection. Immunological Reviews 2009 227 1 75 86 2-s2.0-58049202272 10.1111/j.1600-065X.2008.00737.x
3. Thompson M. R., Kaminski J. J., Kurt-Jones E. A., Fitzgerald K. A., Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011 3 6 920 940 2-s2.0-79959634861 10.3390/v3060920
4. Stetson D. B., Medzhitov R., Type I interferons in host defense. Immunity 2006 25 3 373 381 2-s2.0-33748455338 10.1016/j.immuni.2006.08.007
5. Conticello S. G., Thomas C. J. F., Petersen-Mahrt S. K., Neuberger M. S., Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Molecular Biology and Evolution 2005 22 2 367 377 2-s2.0-11844269804 10.1093/molbev/msi026
6. Muto T., Muramatsu M., Taniwaki M., Kinoshita K., Honjo T., Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. Genomics 2000 68 1 85 88 2-s2.0-0034662680
7. Espinosa R. III, Funahashi T., Hadjiagapiou C., le Beau M. M., Davidson N. O., Assignment of the gene encoding the human apolipoprotein B mRNA editing enzyme (APOBEC1) to chromosome 12p13.1. Genomics 1994 24 2 414 415 2-s2.0-0028559994 10.1006/geno.1994.1645
8. Liao W., Hong S., Chann B. H., Rudolph F. B., Clark S., Chan L., APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochemical and Biophysical Research Communications 1999 260 398 404 10.1006/bbrc.1999.0925
9. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N., An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002 79 3 285 296 2-s2.0-0036200070 10.1006/geno.2002.6718
10. Rogozin I. B., Basu M. K., Jordan I. K., Pavlov Y. I., Koonin E. V., APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 2005 4 9 1281 1285 2-s2.0-25444527785
11. Wedekind J. E., Dance G. S. C., Sowden M. P., Smith H. C., Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends in Genetics 2003 19 4 207 216 2-s2.0-0345270035 10.1016/S0168-9525(03)00054-4
12. Teng B., Burant C. F., Davidson N. O., Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993 260 5115 1816 1818 2-s2.0-0027200620
13. Harris R. S., Petersen-Mahrt S. K., Neuberger M. S., RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Molecular Cell 2002 10 5 1247 1253 2-s2.0-0036863733 10.1016/S1097-2765(02)00742-6
14. Yang Y., Yang Y., Smith H. C., Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing. Proceedings of the National Academy of Sciences of the United States of America 1997 94 24 13075 13080 2-s2.0-0030667958 10.1073/pnas.94.24.13075
15. Lau P. P., Xiong W., Zhu H.-J., Chen S.-H., Chan L., Apolipoprotein B mRNA editing is an intranuclear event that occurs posttranscriptionally coincident with splicing and polyadenylation. The Journal of Biological Chemistry 1991 266 30 20550 20554 2-s2.0-0025749693
16. Sowden M. P., Ballatori N., de Mesy Jensen K. L., Hamilton Reed L., Smith H. C., The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors. Journal of Cell Science 2002 115 5 1027 1039 2-s2.0-0036500884
17. Anant S., Davidson N. O., Molecular mechanisms of apolipoprotein B mRNA editing. Current Opinion in Lipidology 2001 12 2 159 165 2-s2.0-0035083798 10.1097/00041433-200104000-00009
18. Anant S., Davidson N. O., An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3' untranslated region of c-myc increases mRNA stability. Molecular and Cellular Biology 2000 20 6 1982 1992 2-s2.0-0033998026 10.1128/MCB.20.6.1982-1992.2000
19. Rosenberg B. R., Hamilton C. E., Mwangi M. M., Dewell S., Papavasiliou F. N., Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs. Nature Structural & Molecular Biology 2011 18 2 230 238 2-s2.0-79551638596 10.1038/nsmb.1975
20. Dickerson S. K., Market E., Besmer E., Papavasiliou F. N., AID mediates hypermutation by deaminating single stranded DNA. The Journal of Experimental Medicine 2003 197 10 1291 1296 2-s2.0-0037561998 10.1084/jem.20030481
21. Bransteitter R., Pham P., Scharfft M. D., Goodman M. F., Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proceedings of the National Academy of Sciences of the United States of America 2003 100 7 4102 4107 2-s2.0-0037388165 10.1073/pnas.0730835100
22. Rada C., Jarvis J. M., Milstein C., AID-GFP chemirec protein increases hypermutation og Ig genes with no evidence of nuclear localization. Proceedings of the National Academy of Sciences of the United States of America 2002 99 10 7003 7008 2-s2.0-0037076208 10.1073/pnas.092160999
23. Brar S. S., Watson M., Diaz M., Activation-induced cytosine deaminase (AID) is actively exported out of the nucleus but retained by the induction of DNA breaks. The Journal of Biological Chemistry 2004 279 25 26395 26401 2-s2.0-2942722486 10.1074/jbc.M403503200
24. Ito S., Nagaoka H., Shinkura R., Begum N., Muramatsu M., Nakata M., Honjo T., Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proceedings of the National Academy of Sciences of the United States of America 2004 101 7 1975 1980 2-s2.0-1242341972 10.1073/pnas.0307335101
25. McBride K. M., Barreto V., Ramiro A. R., Stavropoulos P., Nussenzweig M. C., Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase. The Journal of Experimental Medicine 2004 199 9 1235 1244 2-s2.0-2442474264 10.1084/jem.20040373
26. Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkai Y., Honjo T., Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000 102 5 553 563 2-s2.0-0034268780
27. Di Noia J. M., Neuberger M. S., Molecular mechanisms of antibody somatic hypermutation. Annual Review of Biochemistry 2007 76 1 22 2-s2.0-34249790004 10.1146/annurev.biochem.76.061705.090740
28. Muramatsu M., Sankaranand V. S., Anant S., Sugai M., Kinoshita K., Davidson N. O., Honjo T., Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. The Journal of Biological Chemistry 1999 274 26 18470 18476 2-s2.0-0033603340 10.1074/jbc.274.26.18470
29. Popp C., Dean W., Feng S., Cokus S. J., Andrews S., Pellegrini M., Jacobsen S. E., Reik W., Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature 2010 463 7284 1101 1105 2-s2.0-77249148019 10.1038/nature08829
30. Bhutani N., Brady J. J., Damian M., Sacco A., Corbel S. Y., Blau H. M., Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010 463 7284 1042 1047 2-s2.0-77649104794 10.1038/nature08752
31. Guo J. U., Su Y., Zhong C., Ming G.-L., Song H., Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011 145 3 423 434 2-s2.0-79955538247 10.1016/j.cell.2011.03.022
32. Sato Y., Probst H. C., Tatsumi R., Ikeuchi Y., Neuberger M. S., Rada C., Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy. The Journal of Biological Chemistry 2010 285 10 7111 7118 2-s2.0-77951218276 10.1074/jbc.M109.052977
33. Wedekind J. E., Gillilan R., Janda A., Krucinska J., Salter J. D., Bennett R. P., Raina J., Smith H. C., Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. The Journal of Biological Chemistry 2006 281 50 38122 38126 2-s2.0-33845972280 10.1074/jbc.C600253200
34. Navarro F., Bollman B., Chen H., König R., Yu Q., Chiles K., Landau N. R., Complementary function of the two catalytic domains of APOBEC3G. Virology 2005 333 2 374 386 2-s2.0-13844270834 10.1016/j.virol.2005.01.011
35. Beale R. C. L., Petersen-Mahrt S. K., Watt I. N., Harris R. S., Rada C., Neuberger M. S., Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. Journal of Molecular Biology 2004 337 3 585 596 2-s2.0-1542328859 10.1016/j.jmb.2004.01.046
36. Armitage A. E., Katzourakis A., de Oliveira T., Welch J. J., Belshaw R., Bishop K. N., Kramer B., McMichael A. J., Rambaut A., Iversen A. K. N., Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. Journal of Virology 2008 82 17 8743 8761 2-s2.0-50149098961 10.1128/JVI.00584-08
37. Bishop K. N., Holmes R. K., Sheehy A. M., Davidson N. O., Cho S.-J., Malim M. H., Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Current Biology 2004 14 15 1392 1396 2-s2.0-4143092717 10.1016/j.cub.2004.06.057
38. Harris R. S., Bishop K. N., Sheehy A. M., Craig H. M., Petersen-Mahrt S. K., Watt I. N., Neuberger M. S., Malim M. H., DNA deamination mediates innate immunity to retroviral infection. Cell 2003 113 6 803 809 2-s2.0-0038681901 10.1016/S0092-8674(03)00423-9
39. Bogerd H. P., Wiegand H. L., Doehle B. P., Lueders K. K., Cullen B. R., APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Research 2006 34 1 89 95 2-s2.0-31644442239 10.1093/nar/gkj416
40. Kinomoto M., Kanno T., Shimura M., Ishizaka Y., Kojima A., Kurata T., Sata T., Tokunaga K., All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Research 2007 35 9 2955 2964 2-s2.0-34250688401 10.1093/nar/gkm181
41. Delebecque F., Suspène R., Calattini S., Casartelli N., Saïb A., Froment A., Wain-Hobson S., Gessain A., Vartanian J.-P., Schwartz O., Restriction of foamy viruses by APOBEC cytidine deaminases. Journal of Virology 2006 80 2 605 614 2-s2.0-30344450447 10.1128/JVI.80.2.605-614.2006
42. Yu Q., Chen D., König R., Mariani R., Unutmaz D., Landau N. R., APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. The Journal of Biological Chemistry 2004 279 51 53379 53386 2-s2.0-11144244647 10.1074/jbc.M408802200
43. Anderson J. L., Hope T. J., APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology 2008 375 1 1 12 2-s2.0-42749089384 10.1016/j.virol.2008.01.042
44. Bishop K. N., Holmes R. K., Malim M. H., Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. Journal of Virology 2006 80 17 8450 8458 2-s2.0-33748640960 10.1128/JVI.00839-06
45. Bishop K. N., Verma M., Kim E.-Y., Wolinsky S. M., Malim M. H., APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathogens 2008 4 12 2-s2.0-58149237802 10.1371/journal.ppat.1000231 e1000231
46. Stenglein M. D., Burns M. B., Li M., Lengyel J., Harris R. S., APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nature Structural & Molecular Biology 2010 17 2 222 229 2-s2.0-76349094670 10.1038/nsmb.1744
47. Suspène R., Aynaud M.-M., Guétard D., Henry M., Eckhoff G., Marchio A., Pineau P., Dejean A., Vartanian J.-P., Wain-Hobson S., Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proceedings of the National Academy of Sciences of the United States of America 2011 108 12 4858 4863 2-s2.0-79953194132 10.1073/pnas.1009687108
48. Burns M. B., Lackey L., Carpenter M. A., APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013 494 366 370 10.1038/nature11881
49. Bennett R. P., Presnyak V., Wedekind J. E., Smith H. C., Nuclear exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding. The Journal of Biological Chemistry 2008 283 12 7320 7327 2-s2.0-43149099925 10.1074/jbc.M708567200
50. Lackey L., Demorest Z. L., Land A. M., Hultquist J. F., Brown W. L., Harris R. S., APOBEC3B and AID have similar nuclear import mechanisms. Journal of Molecular Biology 2012 419 5 301 314 2-s2.0-84860564580 10.1016/j.jmb.2012. 03.011
51. Li M. M. H., Emerman M., Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity. Journal of Virology 2011 85 16 8197 8207 2-s2.0-79961190975 10.1128/JVI.00241-11
52. Land A. M., Law E. K., Carpenter M. A., Lackey L., Brown W. L., Harris R. S., Endogenous APOBEC3A is cytoplasmic and non-genotoxic. The Journal of Biological Chemistry 2013 10.1074/jbc.M113.458661
53. Chiu Y.-L., Soros V. B., Kreisberg J. F., Stopak K., Yonemoto W., Greene W. C., Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005 435 7038 108 114 2-s2.0-18344372631 10.1038/nature03493
54. Chiu Y.-L., Greene W. C., The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annual Review of Immunology 2008 26 317 353 2-s2.0-42649120310 10.1146/annurev.immunol.26.021607.090350
55. Smith H. C., Bennett R. P., Kizilyer A., McDougall W. M., Prohaska K. M., Functions and regulation of the APOBEC family of proteins. Seminars in Cell and Developmental Biology 2012 23 3 258 268 2-s2.0-84860381586 10.1016/j.semcdb. 2011.10.004
56. Wang X., Dolan P. T., Dang Y., Zheng Y.-H., Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. The Journal of Biological Chemistry 2007 282 3 1585 1594 2-s2.0-33847261162 10.1074/jbc.M610150200
57. Tan L., Sarkis P. T. N., Wang T., Tian C., Yu X.-F., Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. The FASEB Journal 2009 23 1 279 287 2-s2.0-58249114897 10.1096/fj.07-088781
58. Niewiadomska A. M., Tian C., Tan L., Wang T., Sarkis P. T. N., Yu X.-F., Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. Journal of Virology 2007 81 17 9577 9583 2-s2.0-34548155661 10.1128/JVI.02800-06
59. Kreisberg J. F., Yonemoto W., Greene W. C., Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. The Journal of Experimental Medicine 2006 203 4 865 870 2-s2.0-33645862586 10.1084/jem.20051856
60. Stopak K. S., Chiu Y.-L., Kropp J., Grant R. M., Greene W. C., Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. The Journal of Biological Chemistry 2007 282 6 3539 3546 2-s2.0-33947518167 10.1074/jbc.M610138200
61. Ellery P. J., Tippett E., Chiu Y.-L., Paukovics G., Cameron P. U., Solomon A., Lewin S. R., Gorry P. R., Jaworowski A., Greene W. C., Sonza S., Crowe S. M., The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. Journal of Immunology 2007 178 10 6581 6589 2-s2.0-34248162439
62. Kamata M., Nagaoka Y., Chen I. S. Y., Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathogens 2009 5 3 2-s2.0-63449095109 10.1371/journal.ppat.1000342 e1000342
63. Santoni de Sio F. R., Trono D., APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection. PLoS ONE 2009 4 8, article e6571 2-s2.0-68749115269 10.1371/journal.pone.0006571
64. Soros V. B., Yonemoto W., Greene W. C., Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathogens 2007 3 2, article e15 2-s2.0-34249940205 10.1371/journal.ppat.0030015
65. Khan M. A., Goila-Gaur R., Kao S., Miyagi E., Walker R. C. Jr., Strebel K., Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology 2009 6, article 1742 2-s2.0-70749116130 10.1186/1742-4690-6-99
66. Ma J., Li X., Xu J., The cellular source for APOBEC3G's incorporation into HIV-1. Retrovirology 2011 8 article 2
67. Chiu Y.-L., Witkowska H. E., Hall S. C., Santiago M., Soros V. B., Esnault C., Heidmann T., Greene W. C., High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proceedings of the National Academy of Sciences of the United States of America 2006 103 42 15588 15593 2-s2.0-33750379905 10.1073/pnas.0604524103
68. Gallois-Montbrun S., Kramer B., Swanson C. M., Byers H., Lynham S., Ward M., Malim M. H., Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. Journal of Virology 2007 81 5 2165 2178 2-s2.0-33847193509 10.1128/JVI.02287-06
69. Gallois-Montbrun S., Holmes R. K., Swanson C. M., Fernández- Ocaña M., Byers H. L., Ward M. A., Malim M. H., Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. Journal of Virology 2008 82 11 5636 5642 2-s2.0-43949090162 10.1128/JVI.00287-08
70. Kozak S. L., Marin M., Rose K. M., Bystrom C., Kabat D., The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. The Journal of Biological Chemistry 2006 281 39 29105 29119 2-s2.0-33749384520 10.1074/jbc.M601901200
71. Wichroski M. J., Robb G. B., Rana T. M., Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathogens 2006 2 5, article e41 2-s2.0-33746063766 10.1371/journal.ppat. 0020041
72. Phalora P. K., Sherer N. M., Wolinsky S. M., Swanson C. M., Malim M. H., HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. Journal of Virology 2012 86 21 11712 11724 10.1128/JVI.00595-12
73. Lada A. G., Frahm Krick C., Kozmin S. G., Mayorov V. I., Karpova T. S., Rogozin I. B., Pavlov Y. I., Mutator effects and mutation signatures of editing deaminases produced in bacteria and yeast. Biochemistry 2011 76 1 131 146 2-s2.0-79952759408 10.1134/S0006297911010135
74. Conticello S. G., Creative deaminases, self-inflicted damage, and genome evolution. Annals of the New York Academy of Sciences 2012 1267 79 85
75. Münk C., Jensen B. E. O., Zielonka J., Häussinger D., Kamp C., Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein. Viruses 2012 4 3132 3161 10.3390/v4113132
76. Severi F., Chicca A., Conticello S. G., Analysis of reptilian APOBEC1 suggests that RNA Editing may not be its ancestral function. Molecular Biology and Evolution 2011 28 3 1125 1129 2-s2.0-79952126772 10.1093/molbev/msq338
77. Harris R. S., Liddament M. T., Retroviral restriction by APOBEC proteins. Nature Reviews Immunology 2004 4 11 868 877 2-s2.0-8544241736 10.1038/nri1489
78. Münk C., Willemsen A., Bravo I., An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evolutionary Biology 2012 12 article 71
79. LaRue R. S., Jónsson S. R., Silverstein K. A. T., Lajoie M., Bertrand D., El-Mabrouk N., Hötzel I., Andrésdóttir V., Smith T. P. L., Harris R. S., The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Molecular Biology 2008 9 104 1 20 2-s2.0-58149307476 10.1186/1471-2199-9-104
80. Münk C., Beck T., Zielonka J., Hotz-Wagenblatt A., Chareza S., Battenberg M., Thielebein J., Cichutek K., Bravo I. G., O'Brien S. J., Löchelt M., Yuhki N., Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biology 2008 9 3, article R48 2-s2.0-45549105119 10.1186/gb-2008-9-3-r48
81. Schumann G. G., APOBEC3 proteins: major players in intracellular defence against LINE-1-mediated retrotransposition. Biochemical Society Transactions 2007 35 3 637 642 2-s2.0-34250870205 10.1042/BST0350637
82. Koito A., Ikeda T., Intrinsic immunity against retrotransposons by APOBEC cytidine deaminases. Frontiers in Microbiology 2013 4 1 9
83. Bogerd H. P., Wiegand H. L., Hulme A. E., Garcia-Perez J. L., O'Shea K. S., Moran J. V., Cullen B. R., Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proceedings of the National Academy of Sciences of the United States of America 2006 103 23 8780 8785 2-s2.0-33745044396 10.1073/pnas.0603313103
84. Hulme A. E., Bogerd H. P., Cullen B. R., Moran J. V., Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 2007 390 1-2 199 205 2-s2.0-33846895873 10.1016/j.gene.2006.08.032
85. Esnault C., Heidmann O., Delebecque F., Dewannieux M., Ribet D., Hance A. J., Heidmann T., Schwartz O., APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005 433 7024 430 433 2-s2.0-13444282074 10.1038/nature03238
86. Esnault C., Millet J., Schwartz O., Heidmann T., Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Research 2006 34 5 1522 1531 2-s2.0-33645529880 10.1093/nar/gkl054
87. Schumacher A. J., Nissley D. V., Harris R. S., APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proceedings of the National Academy of Sciences of the United States of America 2005 102 28 9854 9859 2-s2.0-22244448696 10.1073/pnas.0501694102
88. Macduff D. A., Demorest Z. L., Harris R. S., AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids Research 2009 37 6 1854 1867 2-s2.0-64549103299 10.1093/nar/gkp030
89. Ikeda T., Abd El Galil K. H., Tokunaga K., Maeda K., Sata T., Sakaguchi N., Heidmann T., Koito A., Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons. Nucleic Acids Research 2011 39 13 5538 5554 2-s2.0-80052206764 10.1093/nar/gkr124
90. Metzner M., Jäck H.-M., Wabl M., LINE-1 retroelements complexed and inhibited by activation induced cytidine deaminase. PloS One 2012 7 11, article e49358
91. Bishop K. N., Holmes R. K., Sheehy A. M., Malim M. H., APOBEC-mediated editing of viral RNA. Science 2004 305 5684, article 645 2-s2.0-3442876111 10.1126/science.1100658
92. Ikeda T., Ohsugi T., Kimura T., Matsushita S., Maeda Y., Harada S., Koito A., The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Research 2008 36 21 6859 6871 2-s2.0-57149099407 10.1093/nar/gkn802
93. Petit V., Guétard D., Renard M., Keriel A., Sitbon M., Wain-Hobson S., Vartanian J.-P., Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. Journal of Molecular Biology 2009 385 1 65 78 2-s2.0-57749198859 10.1016/j.jmb.2008.10.043
94. An P., Johnson R., Phair J., Kirk G. D., Yu X.-F., Donfield S., Buchbinder S., Goedert J. J., Winkler C. A., APOBEC3B deletion and risk of HIV-1 acquisition. The Journal of Infectious Diseases 2009 200 7 1054 1058 2-s2.0-70349310335 10.1086/605644
95. Abe H., Ochi H., Maekawa T., Hatakeyama T., Tsuge M., Kitamura S., Kimura T., Miki D., Mitsui F., Hiraga N., Imamura M., Fujimoto Y., Takahashi S., Nakamura Y., Kumada H., Chayama K., Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection. Hepatology Research 2009 39 12 1159 1168 2-s2.0-73849083952 10.1111/j.1872-034X.2009.00566.x
96. Itaya S., Nakajima T., Kaur G., Terunuma H., Ohtani H., Mehra N., Kimura A., No evidence of an association between the APOBEC3B deletion polymorphism and susceptibility to HIV infection and AIDS in Japanese and indian populations. The Journal of Infectious Diseases 2010 202 5 815 816 2-s2.0-77955671317 10.1086/655227
97. Zhang T., Cai J., Chang J., Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. Human Molecular Genetics 2012 22 6 1262 1269
98. Ezzikouri S., Kitab B., Rebbani K., Polymorphic APOBEC3 modulates chronic hepatitis B in Moroccan population. Journal of Viral Hepatitis 2012 1 9 10.1111/jvh.12042
99. An P., Bleiber G., Duggal P., Nelson G., May M., Mangeat B., Alobwede I., Trono D., Vlahov D., Donfield S., Goedert J. J., Phair J., Buchbinder S., O'Brien S. J., Telenti A., Winkler C. A., APOBEC3G genetic variants and their influence on the progression to AIDS. Journal of Virology 2004 78 20 11070 11076 2-s2.0-4644223956 10.1128/JVI.78.20.11070-11076.2004
100. Do H., Vasilescu A., Diop G., Hirtzig T., Heath S. C., Coulonges C., Rappaport J., Therwath A., Lathrop M., Matsuda F., Zagury J.-F., Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. The Journal of Infectious Diseases 2005 191 2 159 163 2-s2.0-19944426225 10.1086/426826
101. Pace C., Keller J., Nolan D., James I., Gaudieri S., Moore C., Mallal S., Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. Journal of Virology 2006 80 18 9259 9269 2-s2.0-33748511879 10.1128/JVI.00888-06
102. Valcke H. S., Bernard N. F., Bruneau J., Alary M., Tsoukas C. M., Roger M., APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 2006 20 15 1984 1986 2-s2.0-33748898695 10.1097/01.aids.0000247124.35129.e1
103. Rathore A., Chatterjee A., Yamamoto N., Dhole T. N., Absence of H186R polymorphism in exon 4 of the APOBEC3G gene among north Indian individuals. Genetic Testing 2008 12 3 453 456 2-s2.0-50649118326 10.1089/gte.2008.0017
104. Reddy K., Winkler C. A., Werner L., Mlisana K., Abdool Karim S. S., Ndung'U T., Apobec3g expression is dysregulated in primary hiv-1 infection and polymorphic variants influence cd4+ t-cell counts and plasma viral load. AIDS 2010 24 2 195 204 2-s2.0-74249120676 10.1097/QAD.0b013e3283353bba
105. de Maio F. A., Rocco C. A., Aulicino P. C., Bologna R., Mangano A., Sen L., Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms. Infection, Genetics and Evolution 2011 11 6 1256 1262 2-s2.0-79960397009 10.1016/j.meegid.2011.04.020
106. Bizinoto M. C., Leal É., Diaz R. S., Janini L. M., Loci polymorphisms of the APOBEC3G gene in HIV type 1-infected Brazilians. AIDS Research and Human Retroviruses 2011 27 2 137 141 2-s2.0-79951707694 10.1089/aid.2010.0146
107. de Maio F. A., Rocco C. A., Aulicino P. C., Bologna R., Mangano A., Sen L., APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability. AIDS Research and Human Retroviruses 2012 28 6 619 627 10.1089/aid.2011.0291
108. Singh K. K., Wang Y., Gray K. P., Genetic variants in the host restriction factor APOBEC3G are associated with HIV-1-related disease progression and central nervous system impairment in children. Journal of Acquired Immune Deficiency Syndromes 2013 62 2 197 203 10.1097/QAI. 0b013e31827ab612
109. Cagliani R., Riva S., Fumagalli M., Biasin M., Caputo S. L., Mazzotta F., Piacentini L., Pozzoli U., Bresolin N., Clerici M., Sironi M., A positively selected APOBEC3H haplotype is associated with natural resistance to HIV-1 infection. Evolution 2011 65 11 3311 3322 2-s2.0-80054901877 10.1111/j.1558-5646.2011.01368.x
110. Gourraud P. A., Karaouni A., Woo J. M., Schmidt T., Oksenberg J. R., Hecht F. M., Liegler T. J., Barbour J. D., APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection. Human Immunology 2011 72 3 207 212 2-s2.0-79651473962 10.1016/j.humimm.2010.12.008
111. Levy J. A., HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 2009 23 2 147 160 2-s2.0-59049094482 10.1097/QAD. 0b013e3283217f9f
112. Cen S., Guo F., Niu M., Saadatmand J., Deflassieux J., Kleiman L., The interaction between HIV-1 gag and APOBEC3G. The Journal of Biological Chemistry 2004 279 32 33177 33184 2-s2.0-4043118380 10.1074/jbc.M402062200
113. Alce T. M., Popik W., APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 gag nucleocapsid protein. The Journal of Biological Chemistry 2004 279 33 34083 34086 2-s2.0-4544232464 10.1074/jbc.C400235200
114. Luo K., Liu B., Xiao Z., Yu Y., Yu X., Gorelick R., Yu X.-F., Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. Journal of Virology 2004 78 21 11841 11852 2-s2.0-6344294123 10.1128/JVI.78.21.11841-11852.2004
115. Zennou V., Perez-Caballero D., Göttlinger H., Bieniasz P. D., APOBEC3G incorporation into human immunodeficiency virus type 1 particles. Journal of Virology 2004 78 21 12058 12061 2-s2.0-6344294871 10.1128/JVI.78.21.12058-12061.2004
116. Douaisi M., Dussart S., Courcoul M., Bessou G., Vigne R., Decroly E., HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochemical and Biophysical Research Communications 2004 321 3 566 573 2-s2.0-4344601964 10.1016/j.bbrc.2004.07.005
117. Schäfer A., Bogerd H. P., Cullen B. R., Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 2004 328 2 163 168 2-s2.0-5344222683 10.1016/j.virol.2004.08.006
118. Svarovskaia E. S., Xu H., Mbisa J. L., Barr R., Gorelick R. J., Ono A., Freed E. O., Hu W.-S., Pathak V. K., Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. The Journal of Biological Chemistry 2004 279 34 35822 35828 2-s2.0-4143124683 10.1074/jbc.M405761200
119. Burnett A., Spearman P., APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. Journal of Virology 2007 81 10 5000 5013 2-s2.0-34248335849 10.1128/JVI.02237-06
120. Wang T., Zhang W., Tian C., Liu B., Yu Y., Ding L., Spearman P., Yu X.-F., Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology 2008 377 1 71 79 2-s2.0-44949182656 10.1016/j.virol.2008.04.012
121. Lecossier D., Bouchonnet F., Clavel F., Hance A. J., Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003 300 5622 1112 2-s2.0-0038363470 10.1126/science.1083338
122. Schröfelbauer B., Yu Q., Zeitlin S. G., Landau N. R., Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG Uracil-DNA glycosylases. Journal of Virology 2005 79 17 10978 10987 2-s2.0-23844471513 10.1128/JVI.79.17.10978-10987.2005
123. Yang B., Chen K., Zhang C., Huang S., Zhang H., Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. The Journal of Biological Chemistry 2007 282 16 11667 11675 2-s2.0-34249671724 10.1074/jbc.M606864200
124. Kaiser S. M., Emerman M., Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. Journal of Virology 2006 80 2 875 882 2-s2.0-30344440118 10.1128/JVI.80.2.875-882.2006
125. Langlois M.-A., Neuberger M. S., Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. Journal of Virology 2008 82 9 4660 4664 2-s2.0-42449109442 10.1128/JVI.02469-07
126. Holmes R. K., Koning F. A., Bishop K. N., Malim M. H., APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation: comparisons with APOBEC3G. The Journal of Biological Chemistry 2007 282 4 2587 2595 2-s2.0-33847625391 10.1074/jbc.M607298200
127. Iwatani Y., Chan D. S. B., Wang F., Maynard K. S., Sugiura W., Gronenborn A. M., Rouzina I., Williams M. C., Musier-Forsyth K., Levin J. G., Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Research 2007 35 21 7096 7108 2-s2.0-37549025779 10.1093/nar/gkm750
128. Newman E. N. C., Holmes R. K., Craig H. M., Klein K. C., Lingappa J. R., Malim M. H., Sheehy A. M., Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current Biology 2005 15 2 166 170 2-s2.0-12544256041 10.1016/j.cub.2004.12.068
129. Mbisa J. L., Barr R., Thomas J. A., Vandegraaff N., Dorweiler I. J., Svarovskaia E. S., Brown W. L., Mansky L. M., Gorelick R. J., Harris R. S., Engelman A., Pathak V. K., Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. Journal of Virology 2007 81 13 7099 7110 2-s2.0-34250880090 10.1128/JVI.00272-07
130. Gillick K., Pollpeter D., Phalora P., Kim E. Y., Wolinsky S. M., Malim M. H., Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4+ T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. Journal of Virology 2013 87 3 1508 1517 10.1128/JVI.02587-12
131. Guo F., Cen S., Niu M., Saadatmand J., Kleiman L., Inhibition of tRNA3Lys-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. Journal of Virology 2006 80 23 11710 11722 2-s2.0-33751206549 10.1128/JVI.01038-06
132. Li X.-Y., Guo F., Zhang L., Kleiman L., Cen S., APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. The Journal of Biological Chemistry 2007 282 44 32065 32074 2-s2.0-36148995875 10.1074/jbc.M703423200
133. Wang X., Ao Z., Chen L., Kobinger G., Peng J., Yao X., The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. Journal of Virology 2012 86 7 3777 3786 10.1128/JVI.06594-11
134. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., Yu X.-F., Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. Journal of Virology 2007 81 13 7238 7248 2-s2.0-34250857925 10.1128/JVI.02584-06
135. Mbisa J. L., Bu W., Pathak V. K., APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. Journal of Virology 2010 84 10 5250 5259 2-s2.0-77951441141 10.1128/JVI.02358-09
136. Casartelli N., Guivel-Benhassine F., Bouziat R., Brandler S., Schwartz O., Moris A., The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. The Journal of Experimental Medicine 2010 207 1 39 49 2-s2.0-76149113235 10.1084/jem.20091933
137. Norman J. M., Mashiba M., McNamara L. A., Onafuwa-Nuga A., Chiari-Fort E., Shen W., Collins K. L., The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nature Immunology 2011 12 10 975 983 2-s2.0-80052966856 10.1038/ni.2087
138. Sheehy A. M., Gaddis N. C., Malim M. H., The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Medicine 2003 9 11 1404 1407 2-s2.0-0344413641 10.1038/nm945
139. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.-F., Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003 302 5647 1056 1060 2-s2.0-0242578406 10.1126/science.1089591
140. Conticello S. G., Harris R. S., Neuberger M. S., The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Current Biology 2003 13 22 2009 2013 2-s2.0-0242709301 10.1016/j.cub.2003.10.034
141. Shirakawa K., Takaori-Kondo A., Kobayashi M., Tomonaga M., Izumi T., Fukunaga K., Sasada A., Abudu A., Miyauchi Y., Akari H., Iwai K., Uchiyama T., Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex. Virology 2006 344 2 263 266 2-s2.0-30044443049 10.1016/j.virol.2005.10.028
142. Mariani R., Chen D., Schröfelbauer B., Navarro F., König R., Bollman B., Münk C., Nymark-McMahon H., Landau N. R., Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003 114 1 21 31 2-s2.0-0038107587 10.1016/S0092-8674(03)00515-4
143. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., Gabuzda D., Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. The Journal of Biological Chemistry 2004 279 9 7792 7798 2-s2.0-1542379821 10.1074/jbc.M313093200
144. Opi S., Kao S., Goila-Gaur R., Khan M. A., Miyagi E., Takeuchi H., Strebel K., Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. Journal of Virology 2007 81 15 8236 8246 2-s2.0-34547130033 10.1128/JVI.02694-06
145. Kao S., Khan M. A., Miyagi E., Plishka R., Buckler-White A., Strebel K., The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. Journal of Virology 2003 77 21 11398 11407 2-s2.0-0142092452 10.1128/JVI.77.21.11398-11407.2003
146. Stopak K., de Noronha C., Yonemoto W., Greene W. C., HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular Cell 2003 12 3 591 601 2-s2.0-0141638436 10.1016/S1097-2765(03)00353-8
147. Mercenne G., Bernacchi S., Richer D., Bec G., Henriet S., Paillart J.-C., Marquet R., HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Research 2009 38 2 633 646 2-s2.0-77449117980 10.1093/nar/gkp1009
148. Chaipan C., Smith J. L., Hu W. S., Pathak V. K., APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. Journal of Virology 2013 87 1 444 453 10.1128/JVI.00676-12
149. Mulder L. C. F., Ooms M., Majdak S., Smedresman J., Linscheid C., Harari A., Kunz A., Simon V., Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. Journal of Virology 2010 84 18 9613 9617 2-s2.0-77956041470 10.1128/JVI.02630-09
150. Liddament M. T., Brown W. L., Schumacher A. J., Harris R. S., APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Current Biology 2004 14 15 1385 1391 2-s2.0-4143071549 10.1016/j.cub.2004.06.050
151. Wiegand H. L., Doehle B. P., Bogerd H. P., Cullen B. R., A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. The EMBO Journal 2004 23 12 2451 2458 2-s2.0-3242712200 10.1038/sj.emboj.7600246
152. Bourara K., Liegler T. J., Grant R. M., Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathogens 2007 3 10 1477 1485 2-s2.0-36048934237 10.1371/journal.ppat.0030153
153. Dang Y., Lai M. S., Wang X., Han Y., Lampen R., Zheng Y.-H., Human cytidine deaminase APOBEC3H restricts HIV-1 replication. The Journal of Biological Chemistry 2008 283 17 11606 11614 2-s2.0-45549100648 10.1074/jbc.M707586200
154. Dang Y., Wang X., Esselman W. J., Zheng Y.-H., Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. Journal of Virology 2006 80 21 10522 10533 2-s2.0-33750344250 10.1128/JVI.01123-06
155. Doehle B. P., Schäfer A., Cullen B. R., Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 2005 339 2 281 288 2-s2.0-23844483541 10.1016/j.virol.2005.06.005
156. Harari A., Ooms M., Mulder L. C. F., Simon V., Polymorphisms and splice variants influence the antiretroviral activity of Human APOBEC3H. Journal of Virology 2009 83 1 295 303 2-s2.0-58149374613 10.1128/JVI.01665-08
157. Wang X., Abudu A., Son S., Dang Y., Venta P. J., Zheng Y.-H., Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. Journal of Virology 2011 85 7 3142 3152 2-s2.0-79952611071 10.1128/JVI.02049-10
158. Albin J. S., Harris R. S., Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Reviews in Molecular Medicine 2010 12 e4 1 26 2-s2.0-77953035055 10.1017/S1462399409001343
159. Vázquez-Pérez J. A., Ormsby C. E., Hernández-Juan R., Torres K. J., Reyes-Terán G., APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 2009 6, article 23 2-s2.0-63549121125 10.1186/1742-4690-6-23
160. Land A. M., Ball T. B., Luo M., Pilon R., Sandstrom P., Embree J. E., Wachihi C., Kimani J., Plummer F. A., Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. Journal of Virology 2008 82 16 8172 8182 2-s2.0-49149090397 10.1128/JVI.01115-08
161. Kourteva Y., de Pasquale M., Allos T., McMunn C., D'Aquila R. T., APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology 2012 430 1 9 10.1016/j.virol.2012.03.018
162. Ulenga N. K., Sarr A. D., Hamel D., Sankale J.-L., Mboup S., Kanki P. J., The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Research and Human Retroviruses 2008 24 10 1285 1290 2-s2.0-53849138762 10.1089/aid.2008.0072
163. Piantadosi A., Humes D., Chohan B., McClelland R. S., Overbaugh J., Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective vif. Journal of Virology 2009 83 16 7805 7814 2-s2.0-67749116433 10.1128/JVI.00280-09
164. Amoêdo N. D., Afonso A. O., Cunha S. M., Oliveira R. H., Machado E. S., Soares M. A., Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression. PloS One 2011 6 8, article e24118 2-s2.0-84855172485
165. Jin X., Brooks A., Chen H., Bennett R., Reichman R., Smith H., APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. Journal of Virology 2005 79 17 11513 11516 2-s2.0-23844483865 10.1128/JVI.79.17.11513-11516.2005
166. Zhao M., Geng W., Jiang Y., Han X., Cui H., Dai D., Bao M., Pan Y., Wang Y., Zhang X., Zhang M., Qi G., Shang H., The associations of hA3G and hA3B mRNA levels with HIV disease progression among HIV-infected individuals of China. Journal of Acquired Immune Deficiency Syndromes 2010 53 supplement 1 S4 S9 2-s2.0-75749096967 10.1097/QAI.0b013e3181c7d349
167. Ulenga N. K., Sarr A. D., Thakore-Meloni S., Sankalé J.-L., Eisen G., Kanki P. J., Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. The Journal of Infectious Diseases 2008 198 4 486 492 2-s2.0-48749099260 10.1086/590212
168. Cho S.-J., Drechsler H., Burke R. C., Arens M. Q., Powderly W., Davidson N. O., APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. Journal of Virology 2006 80 4 2069 2072 2-s2.0-32444434763 10.1128/JVI.80.4.2069-2072.2006
169. Biasin M., Piacentini L., Lo Caputo S., Kanari Y., Magri G., Trabattoni D., Naddeo V., Lopalco L., Clivio A., Cesana E., Fasano F., Bergamaschi C., Mazzotta F., Miyazawa M., Clerici M., Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. The Journal of Infectious Diseases 2007 195 7 960 964 2-s2.0-33947416193 10.1086/511988
170. Ejima T., Hirota M., Mizukami T., Otsuka M., Fujita M., An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G. International Journal of Molecular Medicine 2011 28 4 613 616 2-s2.0-79960755131 10.3892/ijmm.2011.737
171. Cen S., Peng Z.-G., Li X.-Y., Li Z.-R., Ma J., Wang Y.-M., Fan B., You X.-F., Wang Y.-P., Liu F., Shao R.-G., Zhao L.-X., Yu L., Jiang J.-D., Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. The Journal of Biological Chemistry 2010 285 22 16546 16552 2-s2.0-77952781524 10.1074/jbc.M109.085308
172. Nathans R., Cao H., Sharova N., Ali A., Sharkey M., Stranska R., Stevenson M., Rana T. M., Small-molecule inhibition of HIV-1 Vif. Nature Biotechnology 2008 26 10 1187 1192 2-s2.0-53649086178 10.1038/nbt.1496
173. Xiao Z., Ehrlich E., Luo K., Xiong Y., Yu X.-F., Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. The FASEB Journal 2007 21 1 217 222 2-s2.0-33845996549 10.1096/fj.06-6773com
174. Hultquist J. F., Harris R. S., Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virology 2009 4 6 605 619 2-s2.0-73949141798 10.2217/fvl.09.59
175. Mulder L. C. F., Harari A., Simon V., Cytidine deamination induced HIV-1 drug resistance. Proceedings of the National Academy of Sciences of the United States of America 2008 105 14 5501 5506 2-s2.0-44449093971 10.1073/pnas. 0710190105
176. Jern P., Russell R. A., Pathak V. K., Coffin J. M., Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathogens 2009 5 4 e1000367 2-s2.0-66349132212 10.1371/journal.ppat.1000367
177. Wood N., Bhattacharya T., Keele B. F., Giorgi E., Liu M., Gaschen B., Daniels M., Ferrari G., Haynes B. F., McMichael A., Shaw G. M., Hahn B. H., Korber B., Seoighe C., HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathogens 2009 5 5 2-s2.0-67249140561 10.1371/journal.ppat.1000414 e1000414
178. Haché G., Shindo K., Albin J. S., Harris R. S., Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Current Biology 2008 18 11 819 824 2-s2.0-44349179677 10.1016/j.cub.2008.04.073
179. Pillai S. K., Wong J. K., Barbour J. D., Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 2008 5, article 26 2-s2.0-42449152863 10.1186/1742-4690-5-26
180. Kim E.-Y., Bhattacharya T., Kunstman K., Swantek P., Koning F. A., Malim M. H., Wolinsky S. M., Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. Journal of Virology 2010 84 19 10402 10405 2-s2.0-77956828453 10.1128/JVI.01223-10
181. Sadler H. A., Stenglein M. D., Harris R. S., Mansky L. M., APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. Journal of Virology 2010 84 14 7396 7404 2-s2.0-77953769689 10.1128/JVI.00056-10
182. Fourati S., Malet I., Lambert S., E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS 2012 26 13 1619 1624 10.1097/QAD.0b013e3283560703
183. Olson M. E., Li M., Harris R. S., Harki D. A., Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1, 2, 4-triazole-3-thiol scaffold. ChemMedChem 2013 8 112 117 10.1002/cmdc.201200411
184. Li M., Shandilya S. M. D., Carpenter M. A., Rathore A., Brown W. L., Perkins A. L., Harki D. A., Solberg J., Hook D. J., Pandey K. K., Parniak M. A., Johnson J. R., Krogan N. J., Somasundaran M., Ali A., Schiffer C. A., Harris R. S., First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chemical Biology 2012 7 3 506 517 2-s2.0-84858670513 10.1021/cb200440y
185. Matsuoka M., Jeang K.-T., Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nature Reviews Cancer 2007 7 4 270 280 2-s2.0-33947578030 10.1038/nrc2111
186. Kannian P., Green P. L., Human T lymphotropic virus type 1 (HTLV-1): molecular biology and oncogenesis. Viruses 2010 2 9 2037 2077 2-s2.0-79952163857 10.3390/v2092037
187. Richardson J. H., Edwards A. J., Cruickshank J. K., Rudge P., Dalgleish A. G., In vivo cellular tropism of human T-cell leukemia virus type 1. Journal of Virology 1990 64 11 5682 5687 2-s2.0-0025008147
188. Refsland E. W., Stenglein M. D., Shindo K., Albin J. S., Brown W. L., Harris R. S., Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Research 2010 38 13 4274 4284 2-s2.0-77955004656 10.1093/nar/gkq174
189. Ooms M., Krikoni A., Kress A. K., Simon V., Münk C., APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. Journal of Virology 2012 86 11 6097 6108 10.1128/JVI.06570-11
190. Vartanian J.-P., Plikat U., Henry M., Mahieux R., Guillemot L., Meyerhans A., Wain-Hobson S., HIV genetic variation is directed and restricted by DNA precursor availability. Journal of Molecular Biology 1997 270 2 139 151 2-s2.0-0030739032 10.1006/jmbi.1997.1104
191. Fan J., Guangyong M., Nosaka K., Tanabe J., Satou Y., Koito A., Wain-Hobson S., Vartanian J.-P., Matsuoka M., APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. Journal of Virology 2010 84 14 7278 7287 2-s2.0-77953766639 10.1128/JVI.02239-09
192. Mahieux R., Suspène R., Delebecque F., Henry M., Schwartz O., Wain-Hobson S., Vartanian J.-P., Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. Journal of General Virology 2005 86 9 2489 2494 2-s2.0-23844500835 10.1099/vir.0.80973-0
193. Sasada A., Takaori-Kondo A., Shirakawa K., Kobayashi M., Abudu A., Hishizawa M., Imada K., Tanaka Y., Uchiyama T., APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2005 2 1 10 2-s2.0-25444447177 10.1186/1742-4690-2-32
194. Wattel E., Vartanian J.-P., Pannetier C., Wain-Hobson S., Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. Journal of Virology 1995 69 5 2863 2868 2-s2.0-0028932142
195. Cavrois M., Wain-Hobson S., Gessain A., Plumelle Y., Wattel E., Adult T-cell leukemia/lymphoma on a background of clonally expanding human T-cell leukemia virus type-1-positive cells. Blood 1996 88 12 4646 4650 2-s2.0-0029907099
196. Cavrois M., Leclercq I., Gout O., Gessain A., Wain-Hobson S., Wattel E., Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with Tropical spastic paraparesis/HTLV-1 associated myelopathy. Oncogene 1998 17 1 77 82 2-s2.0-0032500171
197. Derse D., Hill S. A., Princler G., Lloyd P., Heidecker G., Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proceedings of the National Academy of Sciences of the United States of America 2007 104 8 2915 2920 2-s2.0-33847244948 10.1073/pnas.0609444104
198. Kao J.-H., Chen D.-S., Global control of hepatitis B virus infection. Lancet Infectious Diseases 2002 2 7 395 403 2-s2.0-0036293243 10.1016/S1473-3099(02)00315-8
199. WHO, HBV Fact Sheet no. 204. http://www.who.int/mediacentre/factsheets/ fs204/en/
200. Gonzalez M. C., Suspène R., Henry M., Guétard D., Wain-Hobson S., Vartanian J.-P., Human APOBEC1 cytidine deaminase edits HBV DNA. Retrovirology 2009 6, article 96 2-s2.0-70450233544 10.1186/1742-4690-6-96
201. Rösler C., Köck J., Kann M., Malim M. H., Blum H. E., Baumert T. F., von Weizsäcker F., APOBEC-mediated interference with hepadnavirus production. Hepatology 2005 42 2 301 309 2-s2.0-23044514707 10.1002/hep.20801
202. Suspène R., Guétard D., Henry M., Sommer P., Wain-Hobson S., Vartanian J.-P., Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 2005 102 23 8321 8326 2-s2.0-20444416733 10.1073/pnas.0408223102
203. Baumert T. F., Rösler C., Malim M. H., von Weizsäcker F., Hepatitis B virus DNA is subject to extensive editing by the human deaminase AP0BEC3C. Hepatology 2007 46 3 682 689 2-s2.0-34548779664 10.1002/hep.21733
204. Köck J., Blum H. E., Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. Journal of General Virology 2008 89 5 1184 1191 2-s2.0-44649185201 10.1099/vir.0.83507-0
205. Henry M., Guétard D., Suspène R., Rusniok C., Wain-Hobson S., Vartanian J.-P., Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS ONE 2009 4 1, article e4277 2-s2.0-59249086363 10.1371/journal.pone.0004277
206. Vartanian J.-P., Henry M., Marchio A., Suspène R., Aynaud M.-M., Guétard D., Cervantes-Gonzalez M., Battiston C., Mazzaferro V., Pineau P., Dejean A., Wain-Hobson S., Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathogens 2010 6 5 e1000928 2-s2.0-77955975678 10.1371/journal.ppat.1000928
207. Turelli P., Mangeat B., Jost S., Vianin S., Trono D., Inhibition of Hepatitis B virus replication by APOBEC3G. Science 2004 303 5665, article 1829 2-s2.0-1642308939 10.1126/science.1092066
208. Nguyen D. H., Gummuluru S., Hu J., Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. Journal of Virology 2007 81 9 4465 4472 2-s2.0-34247635482 10.1128/JVI.02510-06
209. Zhang W., Zhang X., Tian C., Wang T., Sarkis P. T. N., Fang Y., Zheng S., Yu X.-F., Xu R., Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cellular Microbiology 2008 10 1 112 121 2-s2.0-36949041073 10.1111/j.1462-5822. 2007.01020.x
210. Bonvin M., Achermann F., Greeve I., Stroka D., Keogh A., Inderbitzin D., Candinas D., Sommer P., Wain-Hobson S., Vartanian J.-P., Greeve J., Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006 43 6 1364 1374 2-s2.0-33745541663 10.1002/hep.21187
211. Tanaka Y., Marusawa H., Seno H., Matsumoto Y., Ueda Y., Kodama Y., Endo Y., Yamauchi J., Matsumoto T., Takaori-Kondo A., Ikai I., Chiba T., Anti-viral protein APOBEC3G is induced by interferon- α stimulation in human hepatocytes. Biochemical and Biophysical Research Communications 2006 341 2 314 319 2-s2.0-31444449299 10.1016/j.bbrc.2005.12.192
212. Noguchi C., Hiraga N., Mori N., Tsuge M., Imamura M., Takahashi S., Fujimoto Y., Ochi H., Abe H., Maekawa T., Yatsuji H., Shirakawa K., Takaori-Kondo A., Chayama K., Dual effect of APOBEC3G on Hepatitis B virus. Journal of General Virology 2007 88 2 432 440 2-s2.0-33846847836 10.1099/vir.0.82319-0
213. Günther S., Sommer G., Plikat U., Iwanska A., Wain-Hobson S., Will H., Meyerhans A., Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G → A hypermutation. Virology 1997 235 1 104 108 2-s2.0-0342378081 10.1006/viro.1997.8676
214. Margeridon-Thermet S., Shulman N. S., Ahmed A., Shahriar R., Liu T., Wang C., Holmes S. P., Babrzadeh F., Gharizadeh B., Hanczaruk B., Simen B. B., Egholm M., Shafer R. W., Ultra-deep pyrosequencing of hepatitis b virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. The Journal of Infectious Diseases 2009 199 9 1275 1285 2-s2.0-65649130002 10.1086/597808
215. Proto S., Taylor J. A., Chokshi S., Navaratnam N., Naoumov N. V., APOBEC and iNOS are not the main intracellular effectors of IFN- γ -mediated inactivation of Hepatitis B virus replication. Antiviral Research 2008 78 3 260 267 2-s2.0-41049101548 10.1016/j.antiviral.2008.01.006
216. Jost S., Turelli P., Mangeat B., Protzer U., Trono D., Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. Journal of Virology 2007 81 19 10588 10596 2-s2.0-34648834022 10.1128/JVI.02489-06
217. Xu R., Zhang X., Zhang W., Fang Y., Zheng S., Yu X.-F., Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology 2007 46 6 1810 1820 2-s2.0-37449003586 10.1002/hep.21893
218. Moradpour D., Penin F., Rice C. M., Replication of hepatitis C virus. Nature Reviews Microbiology 2007 5 6 453 463 2-s2.0-34249024924 10.1038/nrmicro1645
219. Levrero M., Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006 25 27 3834 3847 2-s2.0-33745527481 10.1038/sj.onc.1209562
220. Peng Z.-G., Zhao Z.-Y., Li Y.-P., Wang Y.-P., Hao L.-H., Fan B., Li Y.-H., Wang Y.-M., Shan Y.-Q., Han Y.-X., Zhu Y.-P., Li J.-R., You X.-F., Li Z.-R., Jiang J.-D., Host apolipoprotein b messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology 2011 53 4 1080 1089 2-s2.0-79953766387 10.1002/hep.24160
221. Komohara Y., Yano H., Shichijo S., Shimotohno K., Itoh K., Yamada A., High expression of APOBEC3G in patients infected with hepatitis C virus. Journal of Molecular Histology 2006 37 8-9 327 332 2-s2.0-33845350483 10.1007/s10735-006-9059-0
222. Jiménez-Sousa M. Á., Almansa R., de la Fuente C., Caro-Patón A., Ruiz L., Sánchez-Antolín G., González J. M., Aller R., Alcaide N., Largo P., Ortiz de Lejarazu R., Bermejo-Martín J. F., Gene expression profiling in the first twelve weeks of treatment in chronic hepatitis C patients. Enfermedades Infecciosas y Microbiologia Clinica 2011 29 8 573 580 2-s2.0-80052963677 10.1016/j.eimc.2011. 04.006
223. Pillai S. K., Abdel-Mohsen M., Guatelli J., Skasko M., Monto A., Fujimoto K., Yukl S., Greene W. C., Kovari H., Rauch A., Fellay J., Battegay M., Hirschel B., Witteck A., Bernasconi E., Ledergerber B., Günthard H. F., Wong J. K., Role of retroviral restriction factors in the interferon- α -mediated suppression of HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America 2012 109 8 3035 3040 2-s2.0-84857374815 10.1073/pnas.1111573109
224. Muñoz N., Castellsagué X., de González A. B., Gissmann L., HPV in the etiology of human cancer. Vaccine 2006 24 supplement 3 S3/1 S3/10
225. Vartanian J.-P., Guétard D., Henry M., Wain-Hobson S., Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 2008 320 5873 230 233 2-s2.0-42049096136 10.1126/science. 1153201
226. Suspène R., Aynaud M.-M., Koch S., Pasdeloup D., Labetoulle M., Gaertner B., Vartanian J.-P., Meyerhans A., Wain-Hobson S., Genetic editing of herpes simplex virus 1 and epstein-barr herpesvirus genomes by Human APOBEC3 cytidine deaminases in culture and in vivo. Journal of Virology 2011 85 15 7594 7602 2-s2.0-79960413190 10.1128/JVI.00290-11
227. Gee P., Ando Y., Kitayama H., Yamamoto S. P., Kanemura Y., Ebina H., Kawaguchi Y., Koyanagi Y., APOBEC1-mediated editing and attenuation of herpes simplex virus 1 DNA indicate that neurons have an antiviral role during herpes simplex encephalitis. Journal of Virology 2011 85 19 9726 9736 2-s2.0-80053989501 10.1128/JVI.05288-11
228. Whitley R. J., Kimberlin D. W., Roizman B., Herpes simplex viruses. Clinical Infectious Diseases 1998 26 3 541 555 2-s2.0-0031957802
229. Whitley R. J., Roizman B., Herpes simplex virus infections. The Lancet 2001 357 9267 1513 1518 2-s2.0-0035849323 10.1016/S0140-6736(00)04638-9
230. Chisholm C., Lopez L., Cutaneous infections caused by herpesviridae: a review. Archives of Pathology and Laboratory Medicine 2011 135 10 1357 1362 2-s2.0-80055078419 10.5858/arpa.2010-0156-RS
231. Mendoza N., Diamantis M., Arora A., Bartlett B., Gewirtzman A., Tremaine A.-M., Tyring S., Mucocutaneous manifestations of Epstein-Barr virus infection. American Journal of Clinical Dermatology 2008 9 5 295 305 2-s2.0-50049133202 10.2165/00128071-200809050-00003
232. Kidd J. M., Newman T. L., Tuzun E., Kaul R., Eichler E. E., Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genetics 2007 3 4, article e63 2-s2.0-34250661464 10.1371/journal.pgen.0030063
233. OhAinle M., Kerns J. A., Li M. M. H., Malik H. S., Emerman M., Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host & Microbe 2008 4 3 249 259 2-s2.0-50849100134 10.1016/j.chom.2008. 07.005
234. An P., Winkler C. A., Host genes associated with HIV/AIDS: advances in gene discovery. Trends in Genetics 2010 26 3 119 131 2-s2.0-76749167054 10.1016/j.tig.2010.01.002
235. Lingappa J. R., Petrovski S., Kahle E., Fellay J., Shianna K., McElrath M. J., Thomas K. K., Baeten J. M., Celum C., Wald A., de Bruyn G., Mullins J. I., Nakku-Joloba E., Farquhar C., Essex M., Donnell D., Kiarie J., Haynes B., Goldstein D., Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PLoS ONE 2011 6 12, article e28632 2-s2.0-83155167585 10.1371/journal.pone.0028632
236. van Manen D., van Wout A. B., Schuitemaker H., Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics. Retrovirology 2012 9 70 1 8 10.1186/1742-4690-9-1
237. Kamatani Y., Wattanapokayakit S., Ochi H., Kawaguchi T., Takahashi A., Hosono N., Kubo M., Tsunoda T., Kamatani N., Kumada H., Puseenam A., Sura T., Daigo Y., Chayama K., Chantratita W., Nakamura Y., Matsuda K., A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nature Genetics 2009 41 5 591 595 2-s2.0-67349160018 10.1038/ng.348
238. Zhang H., Zhai Y., Hu Z., Wu C., Qian J., Jia W., Ma F., Huang W., Yu L., Yue W., Wang Z., Li P., Zhang Y., Liang R., Wei Z., Cui Y., Xie W., Cai M., Yu X., Yuan Y., Xia X., Zhang X., Yang H., Qiu W., Yang J., Gong F., Chen M., Shen H., Lin D., Zeng Y.-X., He F., Zhou G., Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nature Genetics 2010 42 9 755 758 2-s2.0-77956628160 10.1038/ng.638
239. Li S., Qian J., Yang Y., GWAS identifies novel susceptibility loci on 6p21. 32 and 21q21. 3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genetics 2012 8 7 1 8